Adaptive Biotechnologies CCO Bobulsky sells $544k in ADPT stock By Investing.com

Adaptive Biotechnologies reported Q4 EPS of -$0.09 versus a -$0.18 forecast (50% positive surprise) and revenue of $71.7M versus $59.33M expected (+20.85%). The core MRD business grew 54% YoY in Q4 and 46% for the full year. Analysts reacted positively: BTIG raised its price target to $22 (from $21), TD Cowen to $21, and Piper Sandler reiterated Overweight at $20. Insider CCO Susan Bobulsky sold 41,338 shares at $13.17 to cover RSU tax withholding; shares had fallen ~11% over the prior week but are up ~81% over the last year.

Analysis

Adaptive’s MRD momentum creates a two-layer optionality: near-term revenue visibility from recurring test volumes and medium-term margin leverage as fixed lab and bioinformatics costs scale. That dynamics favors multiple expansion more than binary clinical outcomes — every additional 10-15% sustained volume growth materially lifts free-cash-flow conversion within 12–24 months because reagent and software revenue are high-margin and repeatable.

Second-order winners are the compute and server vendors that underpin high-throughput immunosequencing and AI-driven interpretation: durable MRD adoption raises demand for GPU/CPU cycles, validated pipelines, and high-density servers, creating a corridor of commercial partnerships and procurement cycles that benefit suppliers over 2–6 quarters. This also reduces procurement friction for smaller labs who can outsource analytics to cloud/partnered platforms, concentrating commercial power with a handful of platform providers.

Main risks are reimbursement and clinical-pathway adoption sliding timelines — payer coverage or guideline inclusion shifts value realization from quarters to years and can compress multiples sharply if guidance misses. Trading around these outcomes favors defined-risk exposures; the market is currently pricing a mix of growth and execution risk so tactical option structures or sector-hedged equity exposure are preferable to unhedged longs.

Key Decisions for Investors

• Long ADPT equity (ticker: ADPT) — size 1–2% NAV, entry if price < $15; target $25 in 9–12 months (roughly 60–70% upside), hard stop at $11 (limit ~25% downside). Thesis: MRD-driven revenue lift + multiple re-rate; risk: reimbursement or adoption slowdown.
• Defined-risk options (ADPT) — buy 9-month ADPT 12/25 call spread: buy 1x 12 strike, sell 1x 25 strike. Cost-limited, payout if MRD adoption accelerates; breakeven near market + ~20% move; max gain ~2–3x premium if clinical/commercial catalysts hit.
• Pair trade to isolate company vs. sector risk — long ADPT size 1% NAV vs short equal-dollar XBI (or biotech ETF) 0.8–1% NAV. Timeframe 6–12 months: isolates ADPT-specific MRD adoption upside from broad biotech volatility; expected positive carry if ADPT outperforms by >30%.
• Hardware levered play — buy SMCI (ticker: SMCI) or small call position as a 0.5% NAV tactical exposure for 3–6 months to capture incremental server demand from higher sequencing/AI workloads. Risk: enterprise IT spend re-prioritization; reward: >2x upside if adoption drives procurement cycles.